In this clinical update, we bring you the latest news from four gene-editing trials sponsored by Beam Therapeutics, Intellia Therapeutics, Editas...
In this brief update, we bring you the latest news from three gene-editing clinical trials sponsored by Cellectis, Intellia Therapeutics and Caribou...
Clinical data presented at the ASGCT meeting in Baltimore last week revealed that Excision Biotherapeutics' CRISPR-based therapy for HIV is safe but...
Prime Medicine announced this week that the FDA has cleared its investigational new drug application for PM359 for the treatment of chronic...
Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...
In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...
AvenCell Therapeutics recently announced that the first patient has been dosed in a Phase 1A study with its lead product candidate AVC-201. This novel...
HuidaGene Therapeutics recently announced that the FDA has granted Orphan Drug Designation to its CRISPR-based therapeutic candidate, HG302. The...